AD/PD 2019, the 14th​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders takes place in Lisbon, Portugal on March 26-31, 2019.

If you are planning to attend the conference, please stop by and view our recommended posters listed below. Also, you are very welcome to reach out and schedule a meeting with us.

Recommended posters:

Visit event site

Webinar Description:

Progressive neurodegeneration within interconnected brain regions is a common hallmark of several CNS diseases, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). To be able to mimic the spreading of neuropathologies from brain region to brain region poses a particular challenge in CNS disease modelling. Additionally, the absence of high-capacity platforms, reflecting the complexity of progressive neuropathologies and that are suitable for intervention approaches, represent the current bottleneck in disease research and drug discovery campaigns.

To model the spreading of neuropathologies, we have developed a novel microfluidics platform which we combine with our previously established optical electrophysiology technology to create unique high throughput in vitro assays that reflect the hallmarks of the neurodegenerative disease cascade.

In this presentation, we will discuss the design concept and development of this new microfluidic assay platform including a technical validation of the platform. Furthermore, we will show how the platform can be used to model key aspects of Alzheimer´s disease associated neuropathology in primary neuronal cell cultures. We present future outlooks to apply our microfluidic assay platform for in vitro disease modelling for neuromuscular disorders, such ALS and muscular dystrophies, as well as for chronic pain research.

Tuesday March 19 @ 4 pm CET / 11 am EDT / 8 am PDT

Click here for more information and to register for the event.

 

Cellectricon, a collaborative services provider dedicated to advance drug discovery and research in the areas of chronic pain and neurodegenerative disease, is delighted to announce that we will participate in BonePainII, a European Innovative Training Network committed to promote frontline research, innovation and education within bone pain.

Millions of Europeans and beyond suffer from bone pain, which is a debilitating complication of e.g. many musculoskeletal disorders such as arthritis and bone metastasis. Even though the pain affects the quality of life of many people, research on bone pain has been limited. The BonePainII network has participants from six European countries and encompasses eight academic groups and four commercial companies all committed to creating an outstanding training program for 15 early stage researchers (ESRs) to elucidate the mechanisms of bone pain and develop new treatments.

“We are very pleased to be part of the BonePainII network and to be able to exchange knowledge with the neuroscientists and bone researchers within the network” said Cellectricon’s CEO, Dr Mattias Karlsson.

The 15 PhD students will obtain interdisciplinary, state-of-the-art training e.g. by secondments with industrial and academic partners within the network, including some of the foremost pain researchers in Europe. The project is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 814244.

Cellectricon will collaborate with Karolinska Institutet to offer a 4-year PhD fellowship aimed to develop novel methods and assays for assessment of macrophage and bone cell-driven changes in nociceptor excitability in antibody-induced arthritis.

“In the PhD project we are driving, we are looking for a PhD candidate that will participate in the development of novel in vitro assays and technologies to mimic the interactions of a pathological bone environment with sensory neurons.” said Cellectricon’s CSO and Director of Chronic Pain research, Dr Paul Karila. “Example technologies that the student will use are microfluidic-based, compartmentalised chambers for creation of “disease in a dish” systems and high throughput assays. The methodologies developed in the PhD project, in addition to Cellectricon’s established models, will be used to investigate novel biomarkers of osteoarthritis (OA) pain and for drug screening to identify compounds that may be developed into therapeutics for patients suffering from bone pain.”

More information on the PhD position and how to apply. To learn more about the BonePainII network and partners, visit www.bonepain.eu

Background:
We are looking for a new colleague – a driven PhD student with previous experience gained from the pharmaceutical or biotech industry for an open position as PhD fellow in the EU-funded Innovative Training Network BonePainII (www.bonepain.eu). The successful candidate will be given an exciting opportunity to develop novel in vitro assays and methods for mimicking the interactions of pathological tissue with sensory neurons that occur in chronic pain. The resulting knowledge gained during the study may pave the way for new therapeutic options for the millions of people suffering from chronic pain.

About the BonePainII Network:
BonePainII is a European Innovative Training Network to promote frontline research, innovation and education within bone pain. Millions in Europe and beyond suffer from bone pain, which is a debilitating complication of many musculoskeletal disorders such as arthritis and bone metastasis. The BonePainII network has participants from 6 European countries and encompasses 8 academic groups and 4 industries all committed to creating an outstanding training program for 15 early stage researchers (ESRs) to elucidate the mechanisms of bone pain and develop new medicines. This project is part of the EU-funded project BonePainII, (see www.bonepain.eu for more info) and the project is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 814244.

The BonePainII network encompasses academic and industrial partners committed to create an outstanding training program for early stage researchers (ESRs). The students will obtain interdisciplinary, state-of-the-art training e.g. by secondments with industrial and academic partners, including some of the foremost pain researchers in Europe, within the network. The overall goal for the BonePainII network is to train ESRs to become highly skilled and innovative researchers and provide ESRs with expertise that will maximise their future employability and strengthen their career possibilities. This will be achieved by integrated, yet individual research projects, where the ESRs will develop new technologies, identify novel targets, and apply a wide range of cutting-edge techniques to ultimately cure chronic pain.

PhD project title:
Development of novel methods and assays for assessment of macrophage and bone cell driven changes in nociceptor excitability in antibody-induced arthritis.

Project outline:
In the PhD project, the successful candidate will participate in the development of novel in vitro assays, methods and technologies to mimic the interactions of a pathological bone environment with sensory neurons. Example technologies are microfluidic-based, compartmentalised chambers for creation of “disease in a dish” systems and high throughput assays. Subsequently, the developed methodologies, in addition to Cellectricon’s established models, will be used to investigate novel biomarkers of osteoarthritis (OA) pain and for drug screening to identify compounds that may be developed into therapeutics for patients suffering from bone pain.

During the project, the candidate will develop and validate plate-based co-culture systems between DRG neurons and for example macrophages or osteoclasts to understand the interactions between nociceptors with different types of non-neuronal cells relevant for bone pain. Moreover, it will be investigated how antibody-driven activation of macrophages or osteoclasts modulate DRG neuronal excitability and how this can be manipulated pharmacologically.

The company:
Cellectricon is a collaborative services provider dedicated to advance drug discovery and research in the areas of chronic pain and neurodegenerative disease. We are a team of highly experienced neurobiologists, stem cell researchers and engineers, with a proven track record of developing innovative in vitro assays of enhanced translational value for our clients.

What sets us apart from the competition is our proprietary discovery platform. In collaboration with leading academic institutions and pharmaceutical companies, we have over the last 10 years continuously refined and validated our patented core technology to a point where we feel we can establish testing paradigms that are impossible to recreate with other methods. We excel at the generation of high quality primary neuronal cell cultures from e.g. peripheral ganglia, spinal cord and brain, as well as from human iPSC-derived neurons. Our assays fill the gap between less complex model systems, such as high throughput screening in over-expressing cell lines, and in vivo animal models and are enabling our clients to better prioritize which molecules to advance into the clinic.

Required qualifications:
The successful PhD candidate must hold a master’s degree in a relevant scientific discipline (e.g. biomedicine, biotechnology, biomedical engineering, natural sciences or pharmacy).

The candidate must have a minimum of six-to-twelve months experience from an industrial setting (pharmaceutical or biotech company) with hands-on experience and knowledge of the drug discovery process (such as assay development, drug screening in in vitro or in vivo models).

The candidate is expected to be highly motivated, to have good verbal and written English skills and excellent interpersonal and cooperation skills to be able to work on collaborative, challenging research projects that ultimately have commercial utility.

Further, it is desirable that the candidate has a strong interest in neurobiology/neuroscience and has previous experience from cell culturing and primary cell-based assays. Also, experience from assay development and high throughput screening activities (including compound logistics and liquid handling) is desired.

General job description:
Your key tasks as a PhD fellow are to:

  • Manage and carry through your research project
  • Participate in the BonePainII training and network activities
  • Take PhD courses
  • Write scientific articles and your PhD thesis
  • Participate in national and international congresses and scientific meetings
  • Research stay at an external research laboratory within the BonePainII network
  • Disseminate your research

Key criteria for the assessment of applicants:

  • Relevant skills and knowledge
  • Previous publications
  • Relevant work experience
  • The grades achieved during bachelor/master studies
  • Other professional activities
  • Language skills
  • Assessment of the candidate’s motivation letter

Formal requirements, Mobility and eligibility criteria:
The candidate must not have resided or carried out his/her main activity (work, studies, etc.) in Sweden for more than 12 months in the last 3 years immediately prior to his/her recruitment – unless as part of a procedure for obtaining refugee status under the Geneva Convention.

The candidate must be an Early-Stage Researcher (ESR): at the date of recruitment he/she must be in the first four years (full-time equivalent research experience) of his/her research career and must not have been awarded a doctoral degree (more information available here).

For more information regarding the general entry requirements, please see: General entry requirements

Terms of employment:
The terms of employment and salary are in accordance with the local and national rules and in accordance to the rules and regulations laid down by the European Union’s Horizon2020 Marie Sklodowska-Curie Action European Training Network. Exact salary will be confirmed upon appointment.

Position:
The candidate will be employed by and working at Cellectricon, Gothenburg, Sweden and will be registered at the Karolinska Institutet (KI) and affiliated with professor Camilla Svensson’s group. The principal supervisor will be Professor Camilla Svensson, Karolinska Institutet. Email: camilla.svensson@ki.se
Paul Karila, Cellectricon, will serve as main contact and co-supervisor. Email: paul.karila@cellectricon.com, direct phone +46 733 673532.

The graduate program covers four years of full-time study. Rules governing PhD candidates are set out in the Higher Education Ordinance Chapter 5, §§ 1-7 (available here) and in KI’s rules and guidelines. For more information regarding doctoral education at Karolinska Institutet (KI) follow the link.

Type of position:
Full time position, four years

Questions:
For further information, applicants are encouraged to contact the supervisors (see above).

How to apply:
Applicants are requested to submit their application by email to info@cellectricon.com (in Word or pdf format). The application should be written in English and consist of:

  • Cover letter: Letter stating the interest in and qualifications for the project including information about previous experience of industrial research (max. one page).
  • Full CV.
  • List of publications (if any).
  • Diploma and transcripts of records: Master´s degree diploma (including grade transcripts for bachelor´s and master´s degrees). Applicants with a Master´s degree from abroad should also enclose a short description of the grading scale used.
  • Two letters of recommendation including contact details for references.
  • For those applicants whose principal language of instruction during their BSc/MSc was not English it will be an advantage if they enclose IELTS or TOEFL test scores or equivalent proof of English skills.

All documents certifying the entry requirements must be scans of originals (scans of copies or certified copies will not be accepted). The scanned documents must be in color and both the front and the back of the documents must be scanned. Please note that there are specific documentation requirements for a number countries, please read the instructions at: General entry requirements

Deadline for applications:
March 15, 2019.

Applications will be evaluated by an assessment committee consisting of the principal supervisor and 1-2 other members of the BonePainII network or the Department. Short-listed candidates will be invited for an interview (e.g. via Skype). In case of highly qualified, but unsuccessful applications, applicants might have the choice of having their application forwarded to another suitable BonePainII network member for consideration.

Expected starting date:
September 1st, 2019 or earlier.

The 7th World CNS Summit took place in Boston, USA on February 20-21. The meeting is developed with experts from Eisai, Sanofi, Novartis and others, and is an industry-specific conference focused on solving the translational challenges of neurodegenerative research.

If you are interested in learning more about Cellectricon’s drug discovery services you are very welcome to reach out and schedule a meeting with us.

Visit event site

Cellectricon is an innovative discovery services provider in the areas of chronic pain and CNS in vitro research. We are now looking for a laboratory assistant with experience in tissue dissection and cell culture. The employment offers an exciting opportunity to provide important support to our ongoing customer projects.

The work consists of tissue production and seeding, cultivation, and maintenance of cell lines as well as primary cell cultures. The work also includes general laboratory work within the research group, such as preparing solutions and reagents, maintenance of equipment, contributing to experimental activities, as well as being responsible for the purchase and of labware and reagents.

Qualification Requirements: Laboratory Assistant education or equivalent. Expertise within preparation and cultivation of both primary cell cultures and cell lines including animal management, surgical procedures and sterile technique. Approved education in experimental animal science at the University of Gothenburg is highly desirable, as is experience from preparation of primary cultures from nerve tissue – preferably both brain tissue and dorsal root ganglia.

The tasks require accuracy, flexibility, independence and organizational skills. The selected applicant will actively work in several international research projects, therefore we also value collaborative and social skills. In addition, it is a prerequisite with good computer skills and good proficiency in oral (English and Swedish) and written reporting.

Desirable and/or merit in general: A thorough understanding of laboratory equipment and analytical procedures used in the laboratory (e.g. microscopy and immunocytochemistry). Knowledge of various techniques for transfection of genetic material. Driving license for car.

Type of employment: Full-time, fixed salary. The work will mainly be carried out in our premises in Mölndal.

Information about the employment is provided by Johan Pihl. Welcome with your written application, marked “Laboratory Assistant”.

Webinar Description:

The progressive deposition of misfolded Tau protein is a pathological hallmark of several neurodegenerative diseases, collectively called tauopathies, with Alzheimer’s disease being the most prevalent. Despite the progress of research in this field, the underlying molecular mechanisms governing the intercellular aggregation and spreading of Tau assemblies remain elusive. Major limitation has been the translation of mechanistic findings from clonal cell lines, where high throughput screening approaches are more readily available, to functional neuronal models that replicate the phenotypes observed in disease conditions. To address this issue, the aim of our work has focused on the development of functional neuronal screening assays. Challenges and progress of this work will be presented and discussed in line of future opportunities for technical advancements.

Thursday Dec 6 @ 11 am EST

Registration for this event is now closed. Contact us to learn more.


Learning Objectives:

  • Learn about Cellectricon’s new assay platform for functional modelling of prion-like mechanisms
  • Learn about assays and platforms that enable phenotypic screening to identify modifiers of Tau uptake and propagation through genetic and pharmacologic screens
  • Learn more about functional neuronal models to study Tau pathology in relevant neuronal assays using e.g. multichannel microfluidic setups


Speakers:

Thomas Jahn, PhD, Group Leader, Neuroscience Drug Discovery at AbbVie, Germany
Following a Diploma in Biochemistry from the University of Halle (Germany), Thomas moved to the University of Leeds (UK) to receive his PhD in Structural Biology of protein misfolding. Being awarded a Sir Henry Wellcome Postdoctoral Fellowship, he subsequently moved to the University of Cambridge (UK) to work in the Departments of Chemistry and Genetics. During this time, he established a cross-disciplinary team to develop innovative ways to develop and analyze novel models of protein misfolding, with a major focus on Alzheimer’s and Parkinson’s Disease. In 2011 Thomas received funding to establish his independent research group at the University of Heidelberg (Germany). Here, the main research interest of his group focused on proteostasis in neurodegenerative disease, by providing novel methods to recapitulate human disease aspects using cellular and Drosophila models. Thomas joined AbbVie in 2015 where he is a Group Leader in the Neuroscience Discovery organization in Ludwigshafen (Germany).

Sebastian Illes, PhD, Director of CNS research at Cellectricon, Sweden
Sebastian joined Cellectricon in 2018 as director of CNS research. Previously, he held a position as research project leader at the University of Gothenburg. Sebastian did his Post-Doc at the Institute for Molecular Regenerative Medicine (PMU, Salzburg, Austria) and worked as guest researcher at the Natural and Medical Science Institute, Reutlingen, Germany. He holds a diploma in biology with specialisation of neurodevelopment (Ruhr-University-Bochum, Germany) and did his PhD at the neurology department at the Heinrich-Heine University, Duesseldorf, Germany, where he combined for the first time pluripotent stem cell-derived neurons with microelectrode array technology with the specific application in pre-clinical research. Sebastian is still affiliated to University of Gothenburg where he is conducting independent research on human iPSC-derived neuronal circuit models for bipolar disorder, schizophrenia and Alzheimer‘s disease.